When was Merck Sharp & Dohme founded?

Merck Sharp & Dohme was founded in 1890 and raised its 1st funding round 125 years after it was founded.

Where is Merck Sharp & Dohme located?

Merck Sharp & Dohme is headquartered in Kenilworth, United States. It is registered at 120 Moorgate, LONDON EC2M 6UR ENGLAND.

How many employees does Merck Sharp & Dohme have?

As of May 31, 2026, the latest employee count at Merck Sharp & Dohme is 39453.

Is Merck Sharp & Dohme a funded company?

Merck Sharp & Dohme is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2015.

When was the latest funding round of Merck Sharp & Dohme?

Merck Sharp & Dohme's latest funding was a $***** Grant (prize money) round on Oct 01, 2019, with participation from 1 investor.

Where does Merck Sharp & Dohme rank among its competitors?

Merck Sharp & Dohme ranks 60th amongst 1714 active competitors, of which 85 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Merck Sharp & Dohme?

Merck Sharp & Dohme's top competitors include AbbVie, Amgen and Gilead. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Merck Sharp & Dohme - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapies to treat multiple diseases. The company's pipeline include MK-1439A for treating HIV, vaccine V184 for chikungunya virus, V937 for breast cancer, and others. It also, develops a portfolio for diabetes, infectious diseases, and cancer.

Website: www.msd.com/
Social
Phone Number: +1 **********
Registered Address: 120 Moorgate, LONDON EC2M 6UR ENGLAND

Key Metrics

Founded Year

1890

Location

Kenilworth, United States

Stage

Acquired

Latest Funding Round

Grant (prize money), Oct 01, 2019, $*****

Investors

Digital Pharma Lab & 2 more

Ranked

60^th among 1714 active competitors

Employee Count

39,453 as on May 31, 2026

Investment & Acquisitions

Ekincare & 5 more

Similar Companies

AbbVie & 1741 more

Exit Details

Acquired by Onyx Equities (Feb 21, 2023)

View Merck Sharp & Dohme's full profile

Merck Sharp & Dohme is associated with 6 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Merck Sharp & Dohme s.r.o. CIN: 28462564 , Czech Republic, Active	Sep 18, 2008	-	-
MSD Rīga CIN: 43603028328 , Latvia, Active	Sep 20, 2006	€0 - €1M (As on Dec 31, 2025)	2 (As on Dec 31, 2022)	-
MERCK SHARP & DOHME (UK) LIMITED CIN: 928013553 , Norway, Active	Sep 28, 1928	-	-
MSD PHARMACEUTICALS PRIVATE LIMITED CIN: U24230DL2004PTC164459 , India, Active	Dec 03, 2004	₹1,000+ Cr (As on Mar 31, 2025)	-
MSD LLC CIN: 371745630 , United States, Active	Dec 31, 1999	-	202 (As on Dec 31, 2017)	-
MSD (THAILAND) COMPANY LIMITED CIN: 0105555095545 , Thailand, Active	Jul 02, 2012	$50M - $100M (As on Dec 31, 2023)	-

Merck Sharp & Dohme got acquired by Onyx Equities and Machine Investment Group on Feb 21, 2023.

Click here to take a look at Merck Sharp & Dohme's acquisition in detail

Merck Sharp & Dohme has raised funding over 3 rounds. Its first funding round was on Apr 01, 2015. Its latest funding round was a Grant (prize money) round on Oct 01, 2019 for $*****. 1 investor participated in its latest round. Merck Sharp & Dohme has 3 institutional investors.

Here is the list of recent funding rounds of Merck Sharp & Dohme:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 01, 2019	1436944	Grant (prize money)	8729620	5625049	7439202	4476095
Apr 01, 2017	8746328	Grant (prize money)	9221826	5100176	7070781	Europa
Apr 01, 2015	5332467	Grant (prize money)	3746395	8212344	7998950	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Merck Sharp & Dohme's funding rounds and investors

Merck Sharp & Dohme's employee count trend

Merck Sharp & Dohme has 39,453 employees as of May 26. Here is Merck Sharp & Dohme's employee count trend over the years:

Employee count trend for Merck Sharp & Dohme

Uncover Merck Sharp & Dohme's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Merck Sharp & Dohme include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Merck Sharp & Dohme, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Alcor Fund, Berkshire Hathaway & 8 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Jindal ventures, Menlo Ventures & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	79/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	76/100
6th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	73/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	Gershon Capital, Kaccelerator & 7 others	71/100
9th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
10th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, Triodos Investment Management ... & 11 others	70/100
60th	Merck Sharp & Dohme 1890, Kenilworth (United States), Acquired	Developer of therapies to treat multiple diseases	-	Digital Pharma Lab, Water Street & 1 others	55/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Merck Sharp & Dohme's competitors? Click here to see the top ones

Merck Sharp & Dohme has made 4 investments in companies including Ekincare and HD. Merck Sharp & Dohme has also acquired 2 companies including EyeBio and Harpoon Therapeutics.

Here is the list of investments & acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Feb 25, 2025	Investments	Ekincare	2015	Hyderabad (India)
Feb 13, 2025	Investments	HD	2019	Bangkok (Thailand)
May 29, 2024	Acquisition	EyeBio	2021	London (United Kingdom)

Want to know more about where corporates are investing? Sign up today!

See all investments by Merck Sharp & Dohme

Here is the latest report on Merck Sharp & Dohme's geography:

Free

US Fintech Quarter Funding Report

Edition: Quarter 1, 2026 (41 Pages)

View all reports related to Merck Sharp & Dohme

Media has covered Merck Sharp & Dohme for a total of 44 events in the last 1 year, 18 of them have been about company updates and 10 about partnerships.